Literature DB >> 18666721

RCT on gentian violet versus a hydrogel dressing for radiotherapy-induced moist skin desquamation.

S Gollins1, C Gaffney, S Slade, R Swindell.   

Abstract

OBJECTIVE: Radiotherapy-induced moist desquamation is a significant problem but there is a paucity of randomised data on which to base treatment decisions. The current prospective randomised trial compared gentian violet (GV) to a hydrogel dressing in this context.
METHOD: Thirty patients undergoing radiotherapy to the head and neck region or breast who had developed moist desquamation in the radiotherapy field were randomised to treatment with 0.5% aqueous gentian violet (GV) (n=16) or a hydrogel dressing (n=14). The area of desquamation was regularly measured until healing or withdrawal from the study.
RESULTS: The likelihood of healing with the hydrogel was greater than GV with a hazard ratio for healing of 7.95 (95% CI 2.20-28.68; p=0.002). The median time to healing for hydrogel was 12 days but had not been reached for GV by 30 days. Over the first 14 days the median'area under curve' of moist desquamation for GV was 82.6 cm2 (range 31.8-320.7 cm2) and that for hydrogel 20.0 cm2 (range 3.8-301.0 cm2) (difference significant at p=0.003). Ten of 16 patients treated with GV withdrew from the study (due to stinging in five and failure to heal in five) compared with two of the 14 treated with hydrogel (difference significant at p=0.021).
CONCLUSION: Hydrogel dressings are more likely to heal radiotherapy-induced moist desquamation and are better tolerated than GV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18666721     DOI: 10.12968/jowc.2008.17.6.29589

Source DB:  PubMed          Journal:  J Wound Care        ISSN: 0969-0700            Impact factor:   2.072


  9 in total

Review 1.  Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.

Authors:  Rebecca K S Wong; René-Jean Bensadoun; Christine B Boers-Doets; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2013-08-14       Impact factor: 3.603

2.  Response to "Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis".

Authors:  R J Chan
Journal:  Support Care Cancer       Date:  2013-02-08       Impact factor: 3.603

Review 3.  Gentian violet: a 19th century drug re-emerges in the 21st century.

Authors:  Alexander M Maley; Jack L Arbiser
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

Review 4.  Modern Dressings in Prevention and Therapy of Acute and Chronic Radiation Dermatitis-A Literature Review.

Authors:  Konrad Zasadziński; Mateusz Jacek Spałek; Piotr Rutkowski
Journal:  Pharmaceutics       Date:  2022-06-06       Impact factor: 6.525

Review 5.  Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis.

Authors:  Yuejiao Zhang; Shoude Zhang; Xiaoling Shao
Journal:  Support Care Cancer       Date:  2012-10-12       Impact factor: 3.603

6.  Mepilex Lite dressings for managing acute radiation dermatitis in nasopharyngeal carcinoma patients: a systematic controlled clinical trial.

Authors:  Wen-Huan Zhong; Qiong-Fen Tang; Lian-Ying Hu; Hui-Xia Feng
Journal:  Med Oncol       Date:  2013-11-02       Impact factor: 3.064

Review 7.  Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Raymond Javan Chan; Joan Webster; Bryan Chung; Louise Marquart; Muhtashimuddin Ahmed; Stuart Garantziotis
Journal:  BMC Cancer       Date:  2014-01-31       Impact factor: 4.430

Review 8.  Acute radiation dermatitis in breast cancer patients: challenges and solutions.

Authors:  Adam J Kole; Lauren Kole; Meena S Moran
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-05-05

Review 9.  Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.

Authors:  Fleta N Bray; Brian J Simmons; Aaron H Wolfson; Keyvan Nouri
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.